Eribulin-based antibody-drug conjugates and methods of use
Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
1. An antibody-drug conjugate of Formula (I):
Ab-(L-D) p (I)
wherein
Ab is an internalizing anti-folate receptor alpha antibody or internalizing antigen-binding fragment thereof comprising three heavy chain complementarity determining regions (HCDRs) comprising amino acid sequences of SEQ ID NO:2 (HCDR1), SEQ ID NO:3 (HCDR2), and SEQ ID NO:4 (HCDR3); and three light chain complementarity determining regions (LCDRs) comprising amino acid sequences of SEQ ID NO:7 (LCDR1), SEQ ID NO:8 (LCDR2), and SEQ ID NO:9 (LCDR3), as defined by the Kabat numbering system; or three heavy chain complementarity determining regions (HCDRs) comprising amino acid sequences of SEQ ID NO:13 (HCDR1), SEQ ID NO:14 (HCDR2), and SEQ ID NO:15 (HCDR3); and three light chain complementarity determining regions (LCDRs) comprising amino acid sequences of SEQ ID NO:16 (LCDR1), SEQ ID NO:17 (LCDR2), and SEQ ID NO:18 (LCDR3), as defined by the IMGT numbering system;
D is eribulin;
L is a cleavable linker comprising Mal-(PEG) 2 -Val-Cit-pAB; and
p is an integer from 1 to 8.
2. The antibody-drug conjugate of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:23, and a light chain variable region comprising an amino acid sequence of SEQ ID NO:24; and wherein p is an integer from 3 to 4.
3. The antibody-drug conjugate of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG1 heavy chain constant domain and a human Ig kappa light chain constant domain.
4. A pharmaceutical composition comprising the antibody-drug conjugate of claim 1 , and a pharmaceutically acceptable carrier.
5. A composition comprising multiple copies of the antibody-drug conjugate of claim 1 , wherein the average p of the antibody-drug conjugates in the composition is from about 3.2 to about 4.4.
6. A composition comprising multiple copies of an antibody-drug conjugate of Formula (I):
Ab-(L-D) p (I)
wherein
Ab is an internalizing anti-folate receptor alpha antibody or internalizing antigen-binding fragment thereof comprising three heavy chain complementarity determining regions (HCDRs) comprising amino acid sequences of SEQ ID NO:2 (HCDR1), SEQ ID NO:3 (HCDR2), and SEQ ID NO:4 (HCDR3); and three light chain complementarity determining regions (LCDRs) comprising amino acid sequences of SEQ ID NO:7 (LCDR1), SEQ ID NO:8 (LCDR2), and SEQ ID NO:9 (LCDR3), as defined by the Kabat numbering system; or three heavy chain complementarity determining regions (HCDRs) comprising amino acid sequences of SEQ ID NO:13 (HCDR1), SEQ ID NO:14 (HCDR2), and SEQ ID NO:15 (HCDR3); and three light chain complementarity determining regions (LCDRs) comprising amino acid sequences of SEQ ID NO:16 (LCDR1), SEQ ID NO:17 (LCDR2), and SEQ ID NO:18 (LCDR3), as defined by the IMGT numbering system;
D is eribulin;
L is a cleavable linker comprising Mal-(PEG) 2 -Val-Cit-pAB; and
p is the average number of -L-D moieties per Ab, wherein the average p of the antibody-drug conjugates in the composition is from about 3.6 to about 4.4.
7. The composition of claim 6 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:23, and a light chain variable region comprising an amino acid sequence of SEQ ID NO:24.
8. A method of treating a patient having a cancer that expresses folate receptor alpha, comprising administering to the patient a therapeutically effective amount of the antibody-drug conjugate of claim 1 .
9. The method of claim 5 , wherein the cancer is a gastric cancer, a serous ovarian cancer, a clear cell ovarian cancer, a non-small cell lung cancer, a colorectal cancer, a triple negative breast cancer, an endometrial cancer, a lung carcinoid, an osteosarcoma, a bladder cancer, or an urothelial cell carcinoma.
10. The method of claim 8 , wherein the cancer is a serous endometrial carcinoma.
11. A method of reducing or inhibiting growth of a folate receptor alpha-expressing tumor in a patient, comprising administering to the patient a therapeutically effective amount of the antibody-drug conjugate of claim 1 .